Detalhe da pesquisa
1.
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
J Immunother Cancer
; 12(2)2024 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38309722
2.
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
J Thorac Oncol
; 18(8): 1094-1102, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37146752
3.
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases.
NPJ Precis Oncol
; 7(1): 120, 2023 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37964004
4.
Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes.
Int J Cancer
; 131(2): 387-95, 2012 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21964766
5.
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce.
J Immunother Cancer
; 8(1)2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32238470
6.
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
JAMA Oncol
; 3(7): 974-978, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28334399
7.
Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy.
Clin Cancer Res
; 23(12): 3168-3180, 2017 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28193624
8.
TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness.
Cancer Res
; 73(9): 2840-9, 2013 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23447579
9.
Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates.
Hum Gene Ther Methods
; 23(5): 285-96, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23131031